RxDoctor Payments Data

Josephine Chen

Family · Pleasanton, CANPI 1790175214

Payments from drug & device makers

$1,380in general payments, 2019–2025

Across 26 payments — averaging $53.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$241
  • Astellas Pharma US Inc$166
  • Lilly USA, LLC$154
  • GSK$131
  • Regeneron Healthcare Solutions, Inc.$128
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
  • plus $435 from 7 others

What the payments were for

  • Food & beverage$1,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,380 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$80,126
Medicare patients
313
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban31$37,408
EliquisApixaban25$35,893
JardianceEmpagliflozin16$27,799
OzempicSemaglutide20$25,379
JanuviaSitagliptin Phosphate12$19,684
SymbicortBudesonide/Formoterol Fumarate24$5,114
Atorvastatin Calcium139$1,403
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$1,381
Amlodipine Besylate155$1,128
Valsartan14$1,064
Tamsulosin Hcl52$1,051
Losartan Potassium77$987
Lidocaine11$903
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$776
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide24$754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$35,89325 claims
Novo NordiskOzempic$21$25,37920 claims
AstraZenecaSymbicort$122$5,11424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in Pleasanton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →